Marco, IreneLópez Azor García, Juan CarlosGonzález Martín, JavierSevero Sánchez, AndreaGarcía Cosío Carmena, María DoloresMancebo Sierra, María EstherDe Juan Bagudá, JavierCastrodeza Calvo, JavierHernández Pérez, Francisco JoséDelgado Jiménez, Juan Francisco2024-04-252024-04-252023Marco, I.; López-Azor García, J.C.; González Martín, J.; Severo Sánchez, A.; García-Cosío Carmena, M.D.; Mancebo Sierra, E.; de Juan Bagudá, J.; Castrodeza Calvo, J.; Hernández Pérez, F.J.; Delgado, J.F. De Novo Donor-Specific Antibodies after Heart Transplantation: A Comprehensive Guide for Clinicians. J. Clin. Med. 2023, 12, 7474. https:// doi.org/10.3390/jcm122374742077-038310.3390/jcm12237474https://hdl.handle.net/20.500.14352/103490Antibodies directed against donor-specific human leukocyte antigens (HLAs) can be detected de novo after heart transplantation and play a key role in long-term survival. De novo donor-specific antibodies (dnDSAs) have been associated with cardiac allograft vasculopathy, antibody-mediated rejection, and mortality. Advances in detection methods and international guideline recommendations have encouraged the adoption of screening protocols among heart transplant units. However, there is still a lack of consensus about the correct course of action after dnDSA detection. Treatment is usually started when antibody-mediated rejection is present; however, some dnDSAs appear years before graft failure is detected, and at this point, damage may be irreversible. In particular, class II, anti-HLA-DQ, complement binding, and persistent dnDSAs have been associated with worse outcomes. Growing evidence points towards a more aggressive management of dnDSA. For that purpose, better diagnostic tools are needed in order to identify subclinical graft injury. Cardiac magnetic resonance, strain techniques, or coronary physiology parameters could provide valuable information to identify patients at risk. Treatment of dnDSA usually involves plasmapheresis, intravenous immunoglobulin, immunoadsorption, and ritxumab, but the benefit of these therapies is still controversial. Future efforts should focus on establishing effective treatment protocols in order to improve long-term survival of heart transplant recipients.engAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/journal articlehttps://doi.org/10.3390/jcm1223747438068526https://www.mdpi.com/2077-0383/12/23/7474open access616.12Heart transplantationDonor-specific antibodyLate graft dysfunctionAntibody-mediated rejectionImmunosuppressionCardiología3205.01 Cardiología